Focus on Supporting Canadian Labs with Variant-related Assays and QAPs MISSISSAUGA & TORONTO, March 15, 2021 – Microbix Biosystems...

REDxFLOQ SARS-CoV-2 Antigen as IVD Controls in Canada, the EU, and the U.S. MISSISSAUGA, March 11, 2021 – Microbix Biosystems Inc. (TSX:...

Using Shareholder-Approved Plan to Incentivize and Retain MISSISSAUGA, February 18, 2021 - Microbix Biosystems Inc. (TSX: MBX, OTCQB:...

Oneworld Accuracy as a Non-Exclusive Distributor for Africa and Other Territories MISSISSAUGA, February 16, 2021 – Microbix Biosystems...

Record Q1 Sales, With Nearly 3,600% Year-Over-Year QAPs Growth MISSISSAUGA, February 11, 2021 - Microbix Biosystems Inc. (TSX: MBX, OTCQB:...

Initial Production of 50,000 Vials Entirely Sold MISSISSAUGA, February 9, 2021 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF,...

Initial Capacity of 50,000 Vials/Week under Health Canada Regulation MISSISSAUGA, January 28, 2021 – Microbix Biosystems Inc. (TSX: MBX,...

For FLOQ devices & QAPs Co-branding, IP licensing, Co-marketing, Purchase, and Supply MISSISSAUGA, CANADA and BRESCIA, ITALY, December...

Full-Year Sales of $10.5 Million, QAPs Sales Grow by 41%   MISSISSAUGA, December 18, 2020 - Microbix Biosystems Inc. (TSX: MBX,...

Reporting on Test-Workflow Controls for Important Sexually-Transmitted Infections MISSISSAUGA, CANADA, December 15, 2020 – Microbix...

Appointment of Anthony J. Giovinazzo, Accomplished Life Sciences Leader MISSISSAUGA, CANADA, December 7, 2020 – Microbix Biosystems Inc....

Sales Of QAPs™ Kits To Help Qualify Multi-Pathogen Respiratory Test Systems MISSISSAUGA, CANADA, October 29, 2020 – Microbix Biosystems...